MCF Advisors LLC Sells 204,170 Shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX)

MCF Advisors LLC trimmed its position in Poseida Therapeutics, Inc. (NASDAQ:PSTX) by 82.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,854 shares of the company’s stock after selling 204,170 shares during the period. MCF Advisors LLC’s holdings in Poseida Therapeutics were worth $411,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Fred Alger Management LLC bought a new position in Poseida Therapeutics in the 3rd quarter valued at $369,000. Barclays PLC increased its holdings in Poseida Therapeutics by 132.7% during the third quarter. Barclays PLC now owns 120,464 shares of the company’s stock worth $345,000 after buying an additional 68,688 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Poseida Therapeutics by 62.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 359,197 shares of the company’s stock valued at $1,027,000 after acquiring an additional 138,510 shares during the last quarter. Advantage Alpha Capital Partners LP bought a new position in shares of Poseida Therapeutics during the 3rd quarter valued at approximately $285,000. Finally, Renaissance Technologies LLC grew its position in shares of Poseida Therapeutics by 53.4% during the 2nd quarter. Renaissance Technologies LLC now owns 854,900 shares of the company’s stock valued at $2,496,000 after acquiring an additional 297,500 shares during the period. 46.87% of the stock is owned by institutional investors and hedge funds.

Poseida Therapeutics Price Performance

Shares of NASDAQ:PSTX opened at $9.50 on Wednesday. Poseida Therapeutics, Inc. has a 52 week low of $1.87 and a 52 week high of $9.67. The company has a quick ratio of 3.20, a current ratio of 3.20 and a debt-to-equity ratio of 0.68. The stock has a market cap of $928.85 million, a PE ratio of -15.08 and a beta of 1.63. The company’s fifty day moving average is $8.16 and its 200 day moving average is $4.77.

Poseida Therapeutics (NASDAQ:PSTX) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.63. The company had revenue of $71.75 million for the quarter, compared to analysts’ expectations of $15.00 million. Poseida Therapeutics had a negative net margin of 40.28% and a negative return on equity of 72.26%. Research analysts anticipate that Poseida Therapeutics, Inc. will post -1.02 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. BTIG Research restated a “neutral” rating on shares of Poseida Therapeutics in a research note on Tuesday, November 26th. Cantor Fitzgerald cut shares of Poseida Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 26th. William Blair reiterated a “market perform” rating on shares of Poseida Therapeutics in a research note on Tuesday, November 26th. HC Wainwright reaffirmed a “neutral” rating and issued a $9.00 price target (down from $20.00) on shares of Poseida Therapeutics in a report on Tuesday, November 26th. Finally, Piper Sandler lowered Poseida Therapeutics from an “overweight” rating to a “neutral” rating and set a $10.00 price objective on the stock. in a research note on Monday, December 2nd. Five research analysts have rated the stock with a hold rating, According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $9.50.

Insider Activity at Poseida Therapeutics

In other Poseida Therapeutics news, Chairman Mark J. Gergen sold 30,000 shares of Poseida Therapeutics stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $9.46, for a total value of $283,800.00. Following the completion of the sale, the chairman now owns 651,291 shares of the company’s stock, valued at approximately $6,161,212.86. The trade was a 4.40 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 2.90% of the stock is currently owned by insiders.

About Poseida Therapeutics

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.